Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Felypressin→

Felypressin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
56-59-7
Molecular formula
C46H65N13O11S2
Molecular weight
1040.2 g/mol
Drug class
Synthetic vasopressin analoguelocal vasoconstrictor used with selected dental local anaesthetic products
Mechanism of action
Acts on vasopressin V1 receptors in vascular smooth muscle to produce vasoconstriction, reducing local blood flow and prolonging the effect of the accompanying local anaesthetic. It has less direct cardiac stimulation than adrenergic vasoconstrictors.

Sources: NLM MeSH — Felypressin · PubMed review — Vasoconstrictors in local anaesthesia · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Felypressin Environmental Risk Assessment (ERA) (the Felypressin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.